Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial.
The Phase I LuMIERE trial evaluated the safety of [177Lu]Lu-FAP-2286 in 27 heavily pretreated patients with advanced solid tumors.
Why it matters
This study highlights the potential of targeting fibroblast activation protein in advanced solid tumors, providing a foundation for further investigation into the safety and efficacy of radiopharmaceutical therapies in…